Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton C. Ault III Sells 100,000 Shares of Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton C. Ault III sold 100,000 shares of the business’s stock in a transaction on Thursday, July 31st. The shares were sold at an average price of $2.22, for a total transaction of $222,000.00. Following the completion of the transaction, the director directly owned 8,260 shares of the company’s stock, valued at $18,337.20. This trade represents a 92.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alzamend Neuro Price Performance

NASDAQ ALZN opened at $2.20 on Friday. The business has a 50 day simple moving average of $3.18 and a 200 day simple moving average of $6.14. Alzamend Neuro, Inc. has a 52-week low of $2.06 and a 52-week high of $135.54.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Alzamend Neuro from a “sell” rating to a “hold” rating in a report on Saturday, June 14th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alzamend Neuro stock. Citadel Advisors LLC bought a new position in Alzamend Neuro, Inc. (NASDAQ:ALZN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned 0.56% of Alzamend Neuro at the end of the most recent quarter. Institutional investors and hedge funds own 49.61% of the company’s stock.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.